We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals

Delisted

BLCM was delisted on the 1st of June, 2023.

70 hedge funds and large institutions have $371M invested in Bellicum Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more capital inflows, than outflows

Capital inflows: $28.5M | Capital outflows: $10.2M

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

4% more funds holding

Funds holding: 67 → 70 (+3)

3.55% more ownership

Funds ownership: 65.22% → 68.77% (+3.6%)

34% less call options, than puts

Call options by funds: $815K | Put options by funds: $1.24M

Holders
70
Holders Change
+3
Holders Change %
+4.48%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
27
Reduced
19
Closed
7
Calls
$815​K
Puts
$1.24​M
Net Calls
-⁠$428​K
Net Calls Change
-⁠$242​K

BLCM Hedge Fund Activity: Q3 2016 in Review

70 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals (BLCM) for Q3 2016, worth a combined $371M — up 62% from $229M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BLCM positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $18.1M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $2.67M sold.

  • 70 institutional investors held Bellicum Pharmaceuticals (BLCM) as of Q3 2016, up from 67 in Q2 2016.
  • Funds reported $371M of Bellicum Pharmaceuticals stock for Q3 2016, up 62% quarter-over-quarter.
  • 10 funds opened new Bellicum Pharmaceuticals positions in Q3 2016 and 7 closed out, a net change of +3 holders.
  • The largest Bellicum Pharmaceuticals buyer in Q3 2016 was Fidelity Investments, an estimated $18.1M added.
  • The largest Bellicum Pharmaceuticals seller in Q3 2016 was Foresite Capital Management III, an estimated $2.67M sold.

Based on aggregated 13F filings for Q3 2016.